PositiveID Expands Distribution for its Caregiver

DELRAY BEACH, Fla., March 06, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that its Thermomedics Inc. subsidiary (“Thermomedics”), which markets the Caregiver® non-contact thermometer, has entered into a new distribution agreement with National Distribution & Contracting, Inc. (“NDC”). Through this new warehouse vendor agreement, NDC will purchase units of Caregiver and distribute it to its member distributors serving the acute care, alternate site, long-term care and home health segments.

Caregiver, FDA cleared for clinical use, is a professional grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants, without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.

“Expanding the distribution channel for Caregiver is an integral component of our plan to grow its sales, and this new agreement with NDC gives us access to the nation’s largest network of independent healthcare distributors,” stated William J. Caragol, Chairman and CEO of PositiveID. “We believe NDC, which has a long, results-driven history, will help improve the marketing reach and sales efficiency for Caregiver.”

Caregiver requires minimal training and is proven as accurate as other methods of clinical thermometry, which include predictive oral/rectal/axillary electronic, infrared tympanic, temporal artery contact scanner, etc. Other temperature monitoring devices may require protective probe covers, intensive technique concentration, which make them prone to mistaken placement or dwell time, and may require replacement metal probes, cords, or other parts.

About NDC Since 1953, NDC has been a leading global provider of both upstream and downstream healthcare supply chain products and support. NDC offers a wide range of solutions for distributors and manufacturers to deliver efficiency to healthcare. NDC aims to serve its customers by helping to access new markets and products, grow sales, and reduce operating and transaction costs.

About PositiveID Corporation PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com , or connect with PositiveID on Twitter , Facebook or LinkedIn .

Statements about PositiveID's future expectations, including the likelihood that NDC will purchase units of Caregiver and distribute it to its member distributors serving the acute care, alternate site, long-term care and home health segments; the likelihood that since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs; the likelihood that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone; the likelihood that NDC, which has a long, results-driven history, will help improve the marketing reach and sales efficiency for Caregiver; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market; the Company’s ability to attract new customers; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on November 18, 2016, August 12, 2016, and May 16, 2016, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contacts: PositiveID Corporation Allison Tomek (561) 805-8044 RedChip Companies Jon Cunningham (407) 644-4256